NCT04601402 - GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 26, 2020

Primary Completion Date

January 11, 2023

Study Completion Date

January 11, 2023

Conditions

Solid TumorNon Small Cell Lung CancerSquamous Cell Carcinoma of Head and NeckUrothelial Carcinoma

Interventions

DRUG

GEN-001

The capsules taken by mouth once a daily. Each capsule will contain ≥ 1x10\^11 colony-forming units (CFU)

DRUG

Avelumab

800 mg given by intravenous (IV) infusion once every 2 weeks

Trial Locations (3)

Emory University Winship Cancer Institute, Atlanta

Oregon Health & Science University, Portland

Yale Cancer Center, New Haven